Keith C. Ferdinand MD, FACC, FAHA, FNLA, FASHProfessor of Clinical Medicine, Cardiology Division, Tulane University School of Medicine, New Orleans, Louisiana
Dr. Ferdinand was a member of the ALLHAT Data Safety and Monitoring Board and chair of Section Four of the Sixth Report of the Joint National Committee. He was a member of the Ad Hoc Committee on Minority Populations for the National Heart Lung and Blood Institute (NHLBI), and a member of the National High Blood Pressure Education Program Coordinating Committee. He was director of the NHLBI Physician’s Health Network, a program that educated physicians and the lay population on cardiovascular risk reduction.
He is past president and former member of the Louisiana State Board of Medical Examiners, past president of the Orleans Division of the American Heart Association, and past chair of the Board of Association of Black Cardiologists, Inc.
Dr. Ferdinand received his medical degree from Howard University College of Medicine. He is board certified in internal medicine and cardiovascular disease, a diplomat certified in the subspecialty of nuclear cardiology, an American Society of Hypertension certified specialist in clinical hypertension, and a Fellow of the American College of Cardiology, American Heart Association, the National Lipid Association and the American Society of Hypertension. Dr. Ferdinand has written for Cardiology Clinics, Annual of Drug Therapy, and Cardiovascular Diseases in Blacks.Dr. Ferdinand is Editor-in-Chief of the 2009 Educational Review Manual in Cardiovascular Disease (Castle Connolly). He is co-author of Overcoming Katrina African American Voices from the Crescent City and Beyond (Palgrave McMillan 2009), a collection of 27 oral histories. He also is co-editor of Cardiovascular Disease in Racial &Ethnic Minorities (Humana Press 2009).
In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association and the Walter M. Booker Community Service Award of the Association of Black Cardiologists. In 2010 he was recognized by the Congressional Black Caucus Health Trust with an award for journalism and the Charles Drew award for medical excellence in conjunction with the National Minority Quality Foundation.
Advisor/consultant: Astra Zeneca, Sanofi, Amgen
Grant/research support: Eli Lilly, Boerhinger Ingelheim
Recent Contributions to PracticeUpdate:
- Do GLP‐1 Receptor Agonists and SGLT2 Inhibitors Lower CV Events in Black Patients With Type 2 Diabetes?
- Prediabetes and Coexisting Hypertension Increase Cardiovascular Risk
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia
- Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes
- JNC 8 Recommendations for BP Targets Revisited in Older Patients With CAD
- Effect of Self-Monitoring and Medication Self-Titration on Systolic BP in Hypertensive Patients